Progress in the treatment of triple negative breast cancer with sacituzumab govitecan / 国际肿瘤学杂志

Triple-negative breast cancer is a subtype of invasive breast cancer, accounting for about 15% of all breast cancers. Its clinical treatment is relatively difficult, prone to recurrence and metastasis, with a short median survival and poor prognosis. Sacituzumab govitecan is the first approved antigen-coupled drug targeting trophoblast surface antigen 2 in the world. It has significant clinical efficacy, high safety and less adverse reactions, which brings new hope to the treatment of triple-negative breast cancer.